Insider Buying: AstraZeneca PLC (LON:AZN) Insider Buys 20,000 Shares of Stock

AstraZeneca PLC (LON:AZN) insider Pascal Soriot bought 20,000 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was purchased at an average price of £102.03 ($131.30) per share, for a total transaction of £2,040,600 ($2,625,916.87).

AstraZeneca Price Performance

AstraZeneca stock opened at GBX 9,993.35 ($128.60) on Friday. The firm has a market cap of £154.90 billion, a PE ratio of 3,267.30, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The stock’s fifty day moving average price is £117.63 and its two-hundred day moving average price is £121.45. AstraZeneca PLC has a one year low of GBX 9,461 ($121.75) and a one year high of £133.88 ($172.28).

Wall Street Analysts Forecast Growth

Several brokerages have commented on AZN. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. JPMorgan Chase & Co. restated an “overweight” rating and issued a £140 ($180.16) price objective on shares of AstraZeneca in a research note on Thursday, November 7th. Berenberg Bank restated a “buy” rating and issued a £150 ($193.03) price target on shares of AstraZeneca in a research note on Monday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £110 ($141.55) price objective on shares of AstraZeneca in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of £104.12 ($133.99).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.